Alzheimer’s Current Studies

Currently Enrolling Studies

If you or somebody you love is forgetful, has difficulty planning and solving problems, or gets lost in familiar places, it could be a sign of early Alzheimer's disease.

Check out our current enrolling studies below if you are interested in learning more about clinical trials aimed at slowing the progression of Alzheimer's disease. Call us today for more information.

Flyer: Seeking participants for an early Alzheimer's disease clinical trial; features a group of seniors in a variety of settings.

Merck Study

Do you or someone you know have mild cognitive impairment or mild dementia due to Alzheimer’s disease?

Learn about a clinical trial for early Alzheimer’s disease.

Who can join this clinical trial?

There are eligibility criteria that will determine if you qualify to participate. You may be able to join this clinical trial if you:

Are 50-85 years of age
Have mild cognitive impairment or mild dementia due to Alzheimer’s disease
Have a person (trial partner) who can go with you to specific trial visits

Other criteria will apply.

Learn more by contacting us today.

TRAVELLER Study

A study to assess your potential eligibility for Roche Alzheimer’s disease clinical studies. See if you might be a good fit for a Roche Alzheimer’s disease clinical study where treatments are being tested.

You may be able to participate in the TRAVELLER study if you:

Are between 50 and 90 years of age
Have had concerns about your memory or been diagnosed with mild cognitive impairment or mild dementia due to Alzheimer’s disease within the last year

Other criteria will apply.

Learn more by contacting us today.

The BenfoTeam Trial

A new approach for treating early Alzheimer’s disease.

Basic eligibility criteria:

Aged 50-89
Living in the community
Willing to participate in the BenfoTeam study for up to 18 months

Other criteria will apply.

Flyer for Alzheimer's study, asking people with mild Alzheimer's or loved ones to participate. Includes a QR code.

This is a study to investigate the effectiveness of ALLO to regenerate the brain in persons with mild Alzheimer’s. Study participants will be randomly assigned to receive an intravenous infusion of either ALLO or placebo weekly for 12 months. After 12 months, all participants will receive ALLO for the remaining 6 months. This means that for the last 6 months of the study, all of those who were receiving ALLO will continue to receive ALLO, and all those who received placebo will be switched to ALLO treatment. Study procedures include physical and neurological examinations, electrocardiogram (ECG), blood and urine laboratory tests, brain Magnetic Resonance Imaging (MRI) scans, intravenous infusion for 30 minutes once per week, and health questionnaires and assessments that you and your caregiver will complete.

To participate in this study all patients must have the APOE ε4 gene, a risk factor for Alzheimer’s Disease.